CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program

MLA

Raita Heiskanen, et al. “CGTG-102 (Ad5/3-D24-GMCSF), a Novel Oncolytic Adenovirus, in Patients with Refractory Solid Tumors: Experience from an Advanced Therapy Access Program.” Journal of Clinical Oncology, vol. 30, May 2012, p. e13035. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........53ab7af4c45cb756c842e16c99264f40&authtype=sso&custid=ns315887.

APA

Raita Heiskanen, Vincenzo Cerullo, Lotta Kangasniemi, Sari Pesonen, Iulia Diaconu, Petri Nokisalmi, Tuuli Ranki, Akseli Hemminki, Anniina Koski, Mikael von Euler, Timo Joensuu, Minna Oksanen, & Anna Kanerva. (2012). CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program. Journal of Clinical Oncology, 30, e13035.

Chicago

Raita Heiskanen, Vincenzo Cerullo, Lotta Kangasniemi, Sari Pesonen, Iulia Diaconu, Petri Nokisalmi, Tuuli Ranki, et al. 2012. “CGTG-102 (Ad5/3-D24-GMCSF), a Novel Oncolytic Adenovirus, in Patients with Refractory Solid Tumors: Experience from an Advanced Therapy Access Program.” Journal of Clinical Oncology 30 (May): e13035. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........53ab7af4c45cb756c842e16c99264f40&authtype=sso&custid=ns315887.